TriSalus Life Sciences (NASDAQ:TLSI) Earns “Buy” Rating from Roth Mkm

TriSalus Life Sciences (NASDAQ:TLSI)‘s stock had its “buy” rating reiterated by stock analysts at Roth Mkm in a note issued to investors on Friday,Benzinga reports. They currently have a $11.00 target price on the stock. Roth Mkm’s price target indicates a potential upside of 112.36% from the company’s previous close.

A number of other equities research analysts also recently issued reports on the company. Northland Securities began coverage on TriSalus Life Sciences in a research report on Friday, October 25th. They set an “outperform” rating and a $12.50 price target on the stock. Northland Capmk raised TriSalus Life Sciences to a “strong-buy” rating in a report on Friday, October 25th. Canaccord Genuity Group dropped their price target on TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Friday, November 15th. Cantor Fitzgerald assumed coverage on shares of TriSalus Life Sciences in a research note on Tuesday, December 17th. They set an “overweight” rating and a $10.00 price objective on the stock. Finally, Roth Capital upgraded TriSalus Life Sciences to a “strong-buy” rating in a research report on Monday, November 11th. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $11.79.

TriSalus Life Sciences Stock Up 0.4 %

Shares of NASDAQ:TLSI opened at $5.18 on Friday. TriSalus Life Sciences has a 12-month low of $3.50 and a 12-month high of $10.42. The company’s 50 day moving average price is $4.51 and its two-hundred day moving average price is $4.76. The firm has a market cap of $157.94 million, a PE ratio of -2.08 and a beta of 0.51.

Insider Activity

In other news, major shareholder Equity Ab Frankenius purchased 62,972 shares of the company’s stock in a transaction on Tuesday, December 17th. The stock was acquired at an average price of $3.97 per share, with a total value of $249,998.84. Following the transaction, the insider now directly owns 6,230,748 shares of the company’s stock, valued at approximately $24,736,069.56. This represents a 1.02 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last quarter, insiders have purchased 70,012 shares of company stock worth $281,235. 32.80% of the stock is currently owned by corporate insiders.

Institutional Trading of TriSalus Life Sciences

A number of hedge funds have recently modified their holdings of TLSI. Geode Capital Management LLC grew its position in TriSalus Life Sciences by 45.4% in the 3rd quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock worth $924,000 after purchasing an additional 62,542 shares during the period. MSD Partners L.P. bought a new stake in TriSalus Life Sciences during the 3rd quarter valued at approximately $184,000. Vestcor Inc purchased a new position in shares of TriSalus Life Sciences in the third quarter worth $108,000. Virtu Financial LLC bought a new position in shares of TriSalus Life Sciences during the 3rd quarter valued at about $92,000. Finally, Walleye Capital LLC bought a new position in TriSalus Life Sciences during the third quarter valued at approximately $66,000. Institutional investors own 2.58% of the company’s stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.